Pixium Vision SA
PAR:ALPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pixium Vision SA
EPS (Diluted)
Pixium Vision SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pixium Vision SA
PAR:ALPIX
|
EPS (Diluted)
-€6
|
CAGR 3-Years
28%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-3%
|
|
|
Biomerieux SA
PAR:BIM
|
EPS (Diluted)
€3
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
14%
|
|
|
Diagnostic Medical Systems SA
PAR:ALDMS
|
EPS (Diluted)
€0
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
S
|
SMAIO SA
PAR:ALSMA
|
EPS (Diluted)
€0
|
CAGR 3-Years
9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Pixium Vision SA
Glance View
Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
See Also
What is Pixium Vision SA's EPS (Diluted)?
EPS (Diluted)
-6
EUR
Based on the financial report for Jun 30, 2023, Pixium Vision SA's EPS (Diluted) amounts to -6 EUR.
What is Pixium Vision SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
28%
Over the last year, the EPS (Diluted) growth was 48%. The average annual EPS (Diluted) growth rates for Pixium Vision SA have been 28% over the past three years , 28% over the past five years .
